Immunological study of IFNβ-1a-treated and untreated multiple sclerosis patients: Clarifying IFNβ mechanisms and establishing specific dendritic cell immunotherapy

NeuroImmunoModulation

Volumn 12, Issue 1, 2005, Pages 29-44

  Berghella, Anna Maria ^a   Totaro, Rocco ^b   Pellegrini, Patrizia ^a   Contasta, Ida ^a   Russo, Tomassina ^b   Carolei, Antonio ^b   Adorno, Domenico ^a  

^a Ist CNR Per I Trapianti d'O   (Italy)

^b Università Campus Bio Medico   (Italy)

Author keywords

Cytokine network; Dendritic cells; IFN 1a treatment; Immunotherapy; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CD14 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 12; P70 NATURAL KILLER CELL RECEPTOR;

ADULT; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DRUG MECHANISM; EQUILIBRIUM CONSTANT; FEMALE; GENE DELETION; HUMAN; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE; BLOOD; CELL DIFFERENTIATION; COMPARATIVE STUDY; DRUG EFFECT; HELPER CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MONOCYTE; TH1 CELL;

ADULT; ANTIGENS, CD14; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-BETA; INTERLEUKIN-12; MALE; MONOCYTES; MULTIPLE SCLEROSIS; RECEPTORS, IMMUNOLOGIC; SELF TOLERANCE; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS;

EID: 17244380680     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082362     Document Type: Article

References (25)

1. Compston A, Coles A: Multiple sclerosis. Lancet 2002;359:1221-1231.
2. Massacesi L: Compartmentalization of the immune response in the central nervous system and natural history of multiple sclerosis. Implications for therapy. Clin Neurol Neurosurg 2002;104:177-181.
3. Lassmann H: Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin Neurol Neurosurg 2002;104:168-171.
4. Kahl KG, Kruse N, Toyka KV, Rieckmann P: Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J Neurol Sci 2002;200:53-55.
5. Jeffery DR: Early intervention with immunomodulatory agents in the treatment of multiple sclerosis. J Neurol Sci 2002;197:1-8.
6. Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R: Low levels of circulating inflammatory cytokines - Do they affect human brain functions? Brain Behav Immun 2002;16:525-532.
7. Noseworthy JH: Progress in determining the causes and treatment of multiple sclerosis. Nature 1999;399:A40.
8. Holz A, Bielekova B, Martin R, Oldstone MBA: Myelin-associated oligodendrocytic basic protein: Identification of an encephalitogenic epitope and association with multiple sclerosis. J Immunol 2000;164:1103-1109.
9. Rose NR: Autoimmunity at a turning point: From investigation to intervention. Autoimmun Rev 2002;1:3-4.
10. Huang YM, Stoyanova N, Jin YP, Teleshova N, Hussien Y, Xiao BG, Fredrikson S, Link H: Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-β and IL-10. Clin Exp Immunol 2001;124:306-314.
11. Huang YM, Kouwenhoven M, Jin YP, Press R, Huang WX, Link H: Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression. Mult Scler 2001;7:95-99.
12. Duddy ME, Dickson G, Hawkins SA, Armstrong MA: Monocyte-derived dendritic cells: A potential target for therapy in multiple sclerosis (MS). Clin Exp Immunol 2001;123:280-287.
13. Polman CH, Miller DH, McDonald WI, Thompson AJ: Treatment recommendations for interferon-beta in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;67:561-564.
14. Bartholome EJ, Willems F, Crusiaux A, Thielemans K, Schandene L, Goldman M: Interferon-β inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis. Acta Neurol Belg 1999;99:44-52.
15. Huang YM, Hussien Y, Yarilin D, Xiao BG, Liu YJ, Link H: Interferon-β induces the development of type 2 dendritic cells. Cytokine 2001;13:264-271.
16. Bloemena E, Roos MT, Van Heijst JL, Vossen JM, Schellekens PT: Whole-blood lymphocyte cultures. J Immunol Methods 1989;122:161-167.
17. Grigoriadis N: Interferon beta treatment in relapsing-remitting multiple sclerosis. A review. Clin Neurol Neurosurg 2002;104:251-258.
18. Steinman RM, Turley S, Mellman I, Inaba K: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-416.
19. Roncarolo MG, Levings MK, Traversari C: Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001;193:F5-F9.
20. Bridoux F, Badou A, Saoudi A, Bernard I, Druet E, Pasquier R, Druet P, Pelletier L: Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines. J Exp Med 1997;185:1769-1775.
21. Shinomiya M, Fazle Akbar SM, Shinomiya H, Onji M: Transfer of dendritic cells (DC) ex vivo stimulated with interferon-gamma (IFN-gamma) down-modulates autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 1999;117:38-43.
22. Jin YX, Xu LY, Guo H, Ishikawa M, Link H, Xiao BG: TGF-beta1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells. J Autoimmun 2000;14:213-220.
23. Pellegrini P, Berghella AM, Contasta I, Adorno D: CD30 antigen: Not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003;12/1:49-61.
24. Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C: Role of CD30+ T cells in rheumatoid arthritis: A counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001;22:72-77.
25. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR: Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999;398:341-344.